These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

188 related articles for article (PubMed ID: 33378972)

  • 1. Pharmacological inhibition of focal adhesion kinase 1 (FAK1) and anaplastic lymphoma kinase (ALK) identified via kinome profile analysis attenuates lipopolysaccharide-induced endothelial inflammatory activation.
    Dayang EZ; Luxen M; Kuiper T; Yan R; Rangarajan S; van Meurs M; Moser J; Molema G
    Biomed Pharmacother; 2021 Jan; 133():111073. PubMed ID: 33378972
    [TBL] [Abstract][Full Text] [Related]  

  • 2. ALK inhibitor resistance in ALK(F1174L)-driven neuroblastoma is associated with AXL activation and induction of EMT.
    Debruyne DN; Bhatnagar N; Sharma B; Luther W; Moore NF; Cheung NK; Gray NS; George RE
    Oncogene; 2016 Jul; 35(28):3681-91. PubMed ID: 26616860
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Antitumor activity and combined inhibitory effect of ceritinib with gemcitabine in pancreatic cancer.
    Jamshed MB; Munir F; Shahid N; Sadiq U; Muhammad SA; Ghanem NB; Zhong H; Li X; Zhang Q
    Am J Physiol Gastrointest Liver Physiol; 2020 Jan; 318(1):G109-G119. PubMed ID: 31736340
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Role of axl in preeclamptic EPCs functions.
    Hu Y; Liu XP; Liu XX; Zheng YF; Liu WF; Luo ML; Gao H; Zhao Y; Zou L
    J Huazhong Univ Sci Technolog Med Sci; 2016 Jun; 36(3):395-401. PubMed ID: 27376810
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacological inhibitors of anaplastic lymphoma kinase (ALK) induce immunogenic cell death through on-target effects.
    Petrazzuolo A; Perez-Lanzon M; Martins I; Liu P; Kepp O; Minard-Colin V; Maiuri MC; Kroemer G
    Cell Death Dis; 2021 Jul; 12(8):713. PubMed ID: 34272360
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Inhibition of Axl improves the targeted therapy against ALK-mutated neuroblastoma.
    Xu F; Li H; Sun Y
    Biochem Biophys Res Commun; 2014 Nov; 454(4):566-71. PubMed ID: 25450694
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Developmental differences in focal adhesion kinase expression modulate pulmonary endothelial barrier function in response to inflammation.
    Ying L; Alvira CM; Cornfield DN
    Am J Physiol Lung Cell Mol Physiol; 2018 Jul; 315(1):L66-L77. PubMed ID: 29597831
    [TBL] [Abstract][Full Text] [Related]  

  • 8. 3,4,5-Trihydroxycinnamic Acid Inhibits LPS-Induced Inflammatory Response by Increasing SIRT1 Expression in Human Umbilical Vein Endothelial Cells.
    Park JY; Lee HJ; Kwon YS; Chun W
    J Vasc Res; 2020; 57(5):302-310. PubMed ID: 32564014
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The effects of CEP-37440, an inhibitor of focal adhesion kinase, in vitro and in vivo on inflammatory breast cancer cells.
    Salem I; Alsalahi M; Chervoneva I; Aburto LD; Addya S; Ott GR; Ruggeri BA; Cristofanilli M; Fernandez SV
    Breast Cancer Res; 2016 Mar; 18(1):37. PubMed ID: 27009091
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The ALK inhibitors, alectinib and ceritinib, induce ALK-independent and STAT3-dependent glioblastoma cell death.
    Kawauchi D; Takahashi M; Satomi K; Yamamuro S; Kobayashi T; Uchida E; Honda-Kitahara M; Narita Y; Iwadate Y; Ichimura K; Tomiyama A
    Cancer Sci; 2021 Jun; 112(6):2442-2453. PubMed ID: 33728771
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Identification of LPS-Activated Endothelial Subpopulations With Distinct Inflammatory Phenotypes and Regulatory Signaling Mechanisms.
    Dayang EZ; Plantinga J; Ter Ellen B; van Meurs M; Molema G; Moser J
    Front Immunol; 2019; 10():1169. PubMed ID: 31178871
    [TBL] [Abstract][Full Text] [Related]  

  • 12. SHP2 inhibition restores sensitivity in ALK-rearranged non-small-cell lung cancer resistant to ALK inhibitors.
    Dardaei L; Wang HQ; Singh M; Fordjour P; Shaw KX; Yoda S; Kerr G; Yu K; Liang J; Cao Y; Chen Y; Lawrence MS; Langenbucher A; Gainor JF; Friboulet L; Dagogo-Jack I; Myers DT; Labrot E; Ruddy D; Parks M; Lee D; DiCecca RH; Moody S; Hao H; Mohseni M; LaMarche M; Williams J; Hoffmaster K; Caponigro G; Shaw AT; Hata AN; Benes CH; Li F; Engelman JA
    Nat Med; 2018 May; 24(4):512-517. PubMed ID: 29505033
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Angiopoietin-1 inhibits toll-like receptor 4 signalling in cultured endothelial cells: role of miR-146b-5p.
    Echavarria R; Mayaki D; Neel JC; Harel S; Sanchez V; Hussain SN
    Cardiovasc Res; 2015 Jun; 106(3):465-77. PubMed ID: 25824148
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Endotoxin-induced vascular endothelial cell migration is dependent on TLR4/NF-κB pathway, NAD(P)H oxidase activation, and transient receptor potential melastatin 7 calcium channel activity.
    Sarmiento D; Montorfano I; Cáceres M; Echeverría C; Fernández R; Cabello-Verrugio C; Cerda O; Tapia P; Simon F
    Int J Biochem Cell Biol; 2014 Oct; 55():11-23. PubMed ID: 25130439
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Targeting of the AXL receptor tyrosine kinase by small molecule inhibitor leads to AXL cell surface accumulation by impairing the ubiquitin-dependent receptor degradation.
    Lauter M; Weber A; Torka R
    Cell Commun Signal; 2019 Jun; 17(1):59. PubMed ID: 31171001
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Crosstalk between Akt and NF-κB pathway mediates inhibitory effect of gas6 on monocytes-endothelial cells interactions stimulated by P. gingivalis-LPS.
    Wang X; Liu Y; Zhang S; Ouyang X; Wang Y; Jiang Y; An N
    J Cell Mol Med; 2020 Jul; 24(14):7979-7990. PubMed ID: 32462812
    [TBL] [Abstract][Full Text] [Related]  

  • 17. GEF-H1/RhoA signalling pathway mediates lipopolysaccharide-induced intercellular adhesion molecular-1 expression in endothelial cells via activation of p38 and NF-κB.
    Guo F; Zhou Z; Dou Y; Tang J; Gao C; Huan J
    Cytokine; 2012 Mar; 57(3):417-28. PubMed ID: 22226621
    [TBL] [Abstract][Full Text] [Related]  

  • 18. 5-chloro-N4-(2-(isopropylsulfonyl)phenyl)-N2-(2-methoxy-4-(4-((4-methylpiperazin-1-yl)methyl)-1H-1,2,3-triazol-1-yl)phenyl)pyrimidine-2,4-diamine (WY-135), a novel ALK inhibitor, induces cell cycle arrest and apoptosis through inhibiting ALK and its downstream pathways in Karpas299 and H2228 cells.
    Han M; Shen J; Wang L; Wang Y; Zhai X; Li Y; Liu M; Li Z; Zuo D; Wu Y
    Chem Biol Interact; 2018 Mar; 284():24-31. PubMed ID: 29458018
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Overcoming EGFR Bypass Signal-Induced Acquired Resistance to ALK Tyrosine Kinase Inhibitors in ALK-Translocated Lung Cancer.
    Miyawaki M; Yasuda H; Tani T; Hamamoto J; Arai D; Ishioka K; Ohgino K; Nukaga S; Hirano T; Kawada I; Naoki K; Hayashi Y; Betsuyaku T; Soejima K
    Mol Cancer Res; 2017 Jan; 15(1):106-114. PubMed ID: 27707887
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Brigatinib causes tumor shrinkage in both NF2-deficient meningioma and schwannoma through inhibition of multiple tyrosine kinases but not ALK.
    Chang LS; Oblinger JL; Smith AE; Ferrer M; Angus SP; Hawley E; Petrilli AM; Beauchamp RL; Riecken LB; Erdin S; Poi M; Huang J; Bessler WK; Zhang X; Guha R; Thomas C; Burns SS; Gilbert TSK; Jiang L; Li X; Lu Q; Yuan J; He Y; Dixon SAH; Masters A; Jones DR; Yates CW; Haggarty SJ; La Rosa S; Welling DB; Stemmer-Rachamimov AO; Plotkin SR; Gusella JF; Guinney J; Morrison H; Ramesh V; Fernandez-Valle C; Johnson GL; Blakeley JO; Clapp DW;
    PLoS One; 2021; 16(7):e0252048. PubMed ID: 34264955
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.